Related Experiment Video

Updated: May 15, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

[Risk assessment of thrombotic events after the use of activated factor VII]

M C Martínez López1, A J Alcaraz Romero, A B Martínez López

  • 1Servicio de Cuidados Intensivos Pediátricos, Hospital General Universitario Gregorio Marañón, Madrid, España. m.carmen.martinez11@gmail.com

Anales De Pediatria (Barcelona, Spain : 2003)
|December 26, 2012
PubMed

Insights

Recombinant human factor VIIa (rFVIIa) effectively controls severe bleeding in pediatric cardiac surgery. This therapy did not increase thrombotic complications or mortality rates in the postoperative period.

Area of Science:

  • Pediatric Cardiac Surgery
  • Hemostasis and Thrombosis
  • Pharmacology

Background:

  • Severe bleeding is a critical complication in pediatric cardiac surgery.
  • Recombinant human factor VIIa (rFVIIa) is used to manage such bleeding.
  • The thrombotic risk associated with rFVIIa in this population requires investigation.

Purpose of the Study:

  • To analyze the incidence of thrombotic complications in children receiving rFVIIa for severe postoperative bleeding after cardiac surgery.
  • To evaluate the safety and efficacy of rFVIIa in this specific patient group.

Main Methods:

  • A retrospective matched case-control study was conducted.
  • 72 children treated with rFVIIa for severe bleeding post-cardiac surgery were analyzed.
  • A control group of 63 comparable patients was selected based on sex, weight, diagnosis, and surgical risk.

Main Results:

  • No significant difference in thrombosis rates between rFVIIa-treated patients (20%) and controls (28%, P=.540).
  • No significant difference in mortality rates between cases (16%) and controls (9.5%, P=.208).

Conclusions:

  • rFVIIa is effective in controlling severe operative bleeding in pediatric cardiac surgery.
  • rFVIIa therapy does not appear to elevate the risk of thrombotic complications or mortality post-operatively.
  • Findings support the use of rFVIIa as a safe option for managing severe bleeding in pediatric cardiac surgery.
Abstract

Keywords:
Cardiac surgeryCirugía cardiacaEfectos trombóticosFactor vii humano recombinante activoRecombinant human factor viiaThrombotic complications

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...